1)Nakai H, et al : The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol 27 : 1120-1126, 2022
2)Katsumata N, et al : Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer(JGOG 3016) : a randomised, controlled, open-label trial. Lancet Oncol 14 : 1020-1026, 2013
3)Clamp AR, et al : Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment(ICON8) : overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 23 : 919-930, 2022
4)Cancer Genome Atlas Research Network : Integrated genomic analyses of ovarian carcinoma. Nature 474 : 609-615, 2011
5)Kommoss S, et al : Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res 23 : 3794-3801, 2017
6)Murakami R, et al : Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. Gynecol Oncol 141 : 49-56, 2016
7)Murakami R, et al : Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes. Am J Pathol 186 : 1103-1113, 2016
8)Miyagawa C, et al : Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging. J Gynecol Oncol 34 : e47, 2023
9)Ueda A, et al : Artificial intelligence-based histopathological subtyping of high-grade serous ovarian cancer. In review, in submission
10)Burger RA, et al : Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365 : 2473-2483, 2011
11)Perren TJ, et al : A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365 : 2484-2496, 2011
12)Desbois M, et al : Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat Commun 11 : 5583, 2020,
13)Chen RJ, et al : Pan-cancer integrative histology-genomic analysis via multimodal deep learning. Cancer Cell 40 : 865-878.e6, 2022